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Abstract A delayed model describing the dynamics of HIV (Human Immunodeficiency Virus) with CTL
(Cytotoxic T Lymphocytes) immune response is investigated. The model includes four nonlinear differen-
tial equations describing the evolution of uninfected, infected, free HIV viruses, and CTL immune response
cells. It includes also intracellular delay and two treatments (two controls). While the aim of first treatment
consists to block the viral proliferation, the role of the second is to prevent new infections. Firstly, we prove
the well-posedness of the problem by establishing some positivity and boundedness results. Next, we give
some conditions that insure the local asymptotic stability of the endemic and disease-free equilibria. Fi-
nally, an optimal control problem, associated with the intracellular delayed HIV model with CTL immune
response, is posed and investigated. The problem is shown to have an unique solution, which is character-
ized via Pontryagin’s minimum principle for problems with delays. Numerical simulations are performed,
confirming stability of the disease-free and endemic equilibria and illustrating the effectiveness of the two
incorporated treatments via optimal control.
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1 Introduction
Human immunodeficiency virus (HIV) is recognized as a viral pathogen causing the well known acquired
immunodeficiency syndrome (AIDS), which is considered the end-stage of the infection. After this stage,
the immune system fails to play its principal role, which is to protect the whole body against harmful
intruders. This failure is due to destruction of the vast majority of CD4+ T cells by the HIV virus, reducing
them to an account below 200 cells per µ l [1,24].
During last decades, many mathematical models have been developed in order to better understand the
dynamics of the HIV disease [3,11,13,15]. Mathematical models of HIV and tuberculosis coinfection have
been investigated in [18,19]. An interesting case study, with real data from Cape Verde islands, has been
carried out in [20], showing that the goal of the United Nations to end the AIDS epidemic by 2030 is a
nontrivial task. For the importance of optimization techniques and optimal control in the study of HIV,
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we refer the reader to [6,21] and references therein. Here we observe that, often, models introduce the
effect of cellular immune response, also called the cytotoxic T-lymphocyte (CTL) response, which attacks
and kills the infected cells [17]. It has been shown that this cellular immune response can control the
load of HIV viruses [5,22]. In [4], it is assumed that CTL proliferation depends, besides infected cells, as
usual, also on healthy cells. Moreover, an optimal control problem associated with the suggested model is
studied [4]. Recently, the same problem was tackled by introducing time delays [17]. Here, we continue the
investigation of such kind of problems by introducing the HIV virus dynamics to the system of equations.
This is important because uninfected cells must be in contact with the HIV virus before they become
infected. The proposed basic model, illustrating this type of scenario, is as follows:

dx(t)
dt
= λ − dx(t)−β x(t)v(t),
dy(t)
dt
= β x(t)v(t)− ay(t)− py(t)z(t),
dv(t)
dt
= aNy(t)− µv(t),
dz(t)
dt
= cx(t)y(t)z(t)− hz(t),
(1)
subject to given initial conditions x(0) = x0, y(0) = y0, v(0) = v0, and z(0) = z0. In this model, x(t), y(t),
v(t) and z(t) denote, respectively, the concentrations at time t of uninfected cells, infected cells, HIV virus,
and CTL cells. The healthy CD4+ cells grow at a rate λ , decay at a rate dx(t) and become infected by the
virus at a rate β x(t)v(t). Infected cells (y) die at a rate a and are killed by the CTL response at a rate p.
Free virus (v) is produced by the infected cells at a rate aN and decay at a rate µ , where N is the number of
free virus produced by each actively infected cell during its life time. Finally, CTLs (z) expand in response
to viral antigen derived from infected cells at a rate c and decay in the absence of antigenic stimulation at
a rate h.
The paper is organized as follows. Section 2 is devoted to the proof of existence, positivity and bound-
edness of solutions. Then, in Section 3, we do an optimization analysis of the viral infection model. In
Section 4, we construct an appropriate numerical algorithm and give some simulations. Finally, conclu-
sions are given in Section 5.
2 Analysis of the model with delay
In order to be realistic, let us introduce an intracellular time delay to the system of equations (1). Then, the
model takes the following form:

x˙(t) = λ − dx(t)−β x(t)v(t),
y˙(t) = β x(t− τ)v(t− τ)− ay(t)− py(t)z(t),
v˙(t) = aNy(t)− µv(t),
z˙(t) = cx(t)y(t)z(t)− hz(t).
(2)
Here, the delay τ represents the time needed for infected cells to produce virions after viral entry. Model
(2) is a system of delayed ordinary differential equations. For such kind of problems, initial functions
need to be addressed and an appropriate functional framework needs to be specified. Let us first consider
X =C([−τ,0];R4) to be the Banach space of continuous mappings from [−τ,0] to R4 equipped with the
sup-norm ‖ϕ‖= sup
−τ≤t≤0
|ϕ(t)|. We assume that the initial functions verify
(x(θ ),y(θ ),v(θ ),z(θ )) ∈ X . (3)
Also, from biological reasons, these initial functions x(θ ), y(θ ), v(θ ) and z(θ ) have to be nonnegative:
x(θ )≥ 0, y(θ )≥ 0, v(θ )≥ 0, z(θ )≥ 0, for θ ∈ [−τ,0]. (4)
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2.1 Positivity and boundedness of solutions
For the solutions of (2) with initial functions satisfying conditions (3) and (4), the following theorem holds.
Theorem 1 For any initial conditions (x(t),y(t),v(t),z(t)) satisfying (3) and (4), the system (2) has a
unique solution. In addition, the solution is nonnegative and bounded for all t ≥ 0.
Proof By the standard functional framework of ordinary differential equations (see, for instance, [9] and
references therein), we know that there is a unique local solution (x(t),y(t),v(t),z(t)) to system (2) in
[0, tm). From system (2), we have the following:
x(t) = e
−
∫ t
0
(d+β v(ξ ))dξ

x(0)+ ∫ t
0
λ e
∫ η
0
(d +β v(ξ ))dξ
dη

 ,
y(t) = e
−
∫ t
0
(a+ pz(ξ ))dξ

y(0)+ ∫ t
0
β v(η − τ)x(η − τ)e
∫ η
0
(a+ pz(ξ ))dξ
dη

 ,
v(t) = e−µt
(
v(0)+
∫ t
0
aNy(η)eµηdη
)
,
and
z(t) = z(0)e
∫ t
0
(cy(ξ )− h)dξ
.
This shows the positivity of solutions in t ∈ [0, tm). Next, for the boundedness of the solutions, we consider
the following function:
F(t) = aNx(t)+ aNy(t + τ)+
a
2
v(t + τ).
This leads to
dF(t)
dt
= aN (λ − dx(t)−β v(t)x(t))
+ aN (β v(t)x(t)− ay(t + τ)− py(t+ τ)z(t + τ))
+
a
2
(aNy(t + τ)− µv(t+ τ)) ,
from which we have
dF(t)
dt
≤ λ aN− aNdx(t)−
a2N
2
y(t + τ)−
aµ
2
v(t + τ).
If we set ρ =min
(
d,
a
2
,µ
)
, then we have
dF(t)
dt
≤ λ aN−ρF(t).
This proves, via Gronwall’s lemma, that F(t) is bounded, and so are the functions x(t), y(t) and v(t). Now,
we prove the boundedness of z(t). From the last equation of (2), we have
z˙(t)+ hz(t) = cx(t)y(t)z(t).
Moreover, from the second equation of (2), it follows that
z˙(t)+ hz(t) =
c
p
x(t)(β x(t − τ)v(t− τ)− ay(t)− y˙(t)) .
Thus, by integrating over time, we have
z(t) = z(0)e−ht +
∫ t
0
c
p
x(s)(β x(s− τ)v(s− τ)− ay(s)− y˙(s))eh(s−t)ds.
From the boundedness of x, y and v, and by using integration by parts, it follows the boundedness of z(t).
Therefore, every local solution can be prolonged up to any time tm > 0, which means that the solution exists
globally.
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2.2 The linearized problem around the steady-state solution
It is straightforward to establish that model (2) has one disease-free equilibrium given by
E f =
(
λ
d
,0,0,0
)
and two endemic equilibrium points given as follows:
E1 =
(
µ
Nβ
,
λ β N− dµ
aNβ
,
λ β N− dµ
µβ
,0
)
and
E2 =
(
λ µc−β aNh
dµc
,
dhµ
λ µc−β aNh
,
dhaN
λ µc−β aNh
,
β aN
µ p
(
λ µc−β aNh
dµc
)
−
a
p
)
.
Consider now the following transformation:
X(t) = x(t)− x¯, Y (t) = y(t)− y¯, V (t) = v(t)− v¯, Z(t) = z(t)− z¯,
where (x¯, y¯, v¯, z¯) denotes any equilibrium point E f , E1 or E2. The linearized system of the previous model
(2) is of form 

X˙(t) = (−d−β v¯)X(t)−β x¯V (t),
Y˙ (t) = (−a− pz¯)Y (t)+β v¯X(t− τ)+β x¯V (t − τ)− py¯Z(t),
V˙ (t) = aNY (t)− µV(t),
Z˙(t) = cy¯z¯X(t)+ cx¯z¯Y (t)+ (cx¯y¯− h)Z(t).
(5)
System (5) can be written in matrix form as follows:
d
dt


X(t)
Y (t)
V (t)
Z(t)

= A1


X(t)
Y (t)
V (t)
Z(t)

+A2


X(t− τ)
Y (t− τ)
V (t− τ)
Z(t − τ)

 ,
where A1 and A2 are the two matrices given by
A1 =


−d−β v¯ 0 −β x¯ 0
0 −a− pz¯ 0 −py¯
0 aN −µ 0
cy¯z¯ cx¯z¯ 0 cx¯y¯− h


and
A2 =


0 0 0 0
β v¯ 0 β x¯ 0
0 0 0 0
0 0 0 0

 .
2.3 Stability of the disease-free equilibrium
We begin by studying the stability of the disease-free equilibrium E f . The following result holds.
Theorem 2 The local stability of the disease-free equilibrium E f depends on the value of Nβ λ − dµ .
Precisely, we have:
1. if Nβ λ − dµ < 0, then the disease-free equilibrium E f is locally asymptotically stable for any time
delay τ ≥ 0;
2. if Nβ λ − dµ > 0, then the equilibrium E f is unstable for any time delay τ ≥ 0.
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Proof The characteristic equation of system (2) is given by
∆(ζ ) = det(ζ Id−A1− e
−ζτA2) = 0. (6)
Thus, at the disease-free equilibrium, the characteristic equation takes the form
(ζ + d)(ζ + h)
[
ζ 2+(µ + a)ζ + aµ
(
1−
Nβ λ
dµ
e−ζτ
)]
= 0. (7)
If we assume τ = 0, then equation (7) becomes
(ζ + d)(ζ + h)
[
ζ 2+(µ + a)ζ + aµ
(
1−
Nβ λ
dµ
)]
= 0. (8)
The four roots of (8) are:
ζ1 =−d,
ζ2 =−h,
ζ3 =
−(µ + a)−
√
(µ + a)2− 4aµ
(
1− Nβ λ
dµ
)
2
,
ζ4 =
−(µ + a)+
√
(µ + a)2− 4aµ(1− Nβ λ
dµ )
2
.
It is clear that ζ1, ζ2 and ζ3 have negative real parts, while ζ4 has negative real part if Nβ λ − dµ < 0.
Suppose that τ > 0. To prove the stability of E f , we use Rouche´’s theorem. For that, we need to prove
that the roots of the characteristic equation (7) cannot have pure imaginary roots, that is, cannot cross
the imaginary axis. Suppose the contrary. Let ζ = ω i with ω > 0 a purely imaginary root of (7). Then,
(ω i)2+(µ + a)(ω i)+ aµ
(
1− Nβ λ
dµ e
−iωτ
)
= 0, that is, −ω2+(µ + a)ω i+ aµ
(
1− Nβ λ
dµ e
−iωτ
)
= 0. By
using Euler’s formula e−iωτ = cos(ωτ)− isin(ωτ) and by separating the real imaginary parts, we have

−ω2+ aµ =
aNβ λ
d
cos(ωτ)
(a+ µ)ω =−
aNβ λ
d
sin(ωτ).
Adding the squares in the two equations, one obtains
ω4+
(
a2+ µ2
)
ω2+ a2µ2
(
1−
(
Nβ λ
dµ
)2)
= 0.
Let X = ω2. We have
X2+
(
a2+ µ2
)
X + a2µ2
(
1−
(
Nβ λ
dµ
)2)
= 0,
which has no positive solution when Nβ λ − dµ < 0. Therefore, there is no root ζ = iω with ω ≥ 0 for
(7), implying that the root of (7) cannot intersect the pure imaginary axis. Therefore, all roots of (7) have
negative real parts Nβ λ − dµ < 0 and the disease-free equilibrium, E f , is locally asymptotically stable if
Nβ λ −dµ < 0. In addition, it is easy to show that (7) has a real positive root when Nβ λ −dµ > 0. Indeed,
let us put
f (ζ ) = ζ 2+(µ + a)ζ + aµ
(
1−
Nβ λ
dµ
e−ζτ
)
.
Then, f (0) = aµ
(
1− Nβ λ
dµ
)
> 0 and limζ→+∞ f (ζ ) = +∞. Consequently, f has a positive real root and
the disease-free equilibrium is unstable.
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2.4 Stability of the endemic equilibria
We start by studying the local stability of the infected-equilibrium E1 for any time delay τ .
Theorem 3 The local stability of the disease-free equilibrium E1 depends on the value of
β N(µcλ −β haN)− µ2cd.
Precisely, we have:
1. if β N(µcλ −β haN)−µ2cd < 0, then E1 is locally asymptotically stable for any positive time delay τ;
2. if β N(µcλ −β haN)− µ2cd > 0, then E1 is unstable for any positive time delay τ .
Proof Let λ β N− dµ > 0 and µcλ −β haN > 0. The characteristic equation (6) at E1 is given by
(ζ − cx¯y¯+ h)
(
ζ 3+Aζ 2+Bζ +C− e−ζτ (g1ζ + g2)
)
= 0, (9)
where
A = d + µ + a+β v¯,
B = µd + ad+ aµ + µβ v¯,
C = aµ(d+β v¯)−β aNdx¯,
g1 = β aNx¯,
g2 = β aNdx¯.
Note that
ζ =
β N (µcλ −β haN)− µ2cd
aN2β 2
(10)
is a solution of (9). If β N(µcλ −β haN)− µ2cd < 0, then (10) is a real negative root of the characteristic
equation (9), and we just need to analyze equation
ζ 3+Aζ 2+Bζ +C− e−ζτ(g1ζ + g2) = 0. (11)
Consider now τ = 0. From equation (11), we have
ζ 3+Pζ 2+Qζ +R = 0, (12)
where
P = d + µ + a+β v¯,
Q = µd+ ad+ aµ + µβ v¯− aNβ x¯,
R = aµ(d+β v¯)− 2β aNdx¯.
Because β Nλ − dµ > 0, from the Routh–Hurwitz stability criterion, it follows that all roots of (12) have
negative real part. Thus, E1 is locally asymptotically stable for τ = 0. Let τ > 0. Suppose that (9) has pure
imaginary roots ζ = ω i with ω > 0. If we replace ζ in (11) by ζ = ω i, and separate the real and imaginary
parts, then we obtain {
−Aω2+C = g2 cos(ωτ)+ g1ω sin(ωτ),
−ω3+Bω = g1ω cos(ωτ)− g2 sin(ωτ).
By adding up the squares of the two equations, and by using the fundamental trigonometric formula, we
obtain that
ω6+(A2− 2B)ω4+(B2− 2AC− g21)ω
2+C2− g22 = 0.
Letting X = ω2, yields
F(X) = X3+(A2− 2B)X2+(B2− 2AC− g21)X +C
2− g22 = 0.
We have F(0) = λ 2β 2a2N2− a2µ2d2 > 0 and limζ→+∞ f (ζ ) = +∞. Hence, (11) has no positive solution
because λ β N − dµ > 0. Therefore, there is no root ζ = ω i with ω > 0 for (11), implying that the root
of (11) cannot cross the purely imaginary axis. Thus, all roots of (9) have negative real parts. Then, E1 is
locally asymptotically stable when β N(µcλ −β haN)− µ2cd < 0.
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For the second endemic equilibrium point E2, the following result holds.
Theorem 4 Assume that λ µc−β aNh> 0. If β N(λ µc−β haN)−µ2cd > 0, then the infected equilibrium
E2 is locally asymptotically stable for τ = 0.
Proof Let β N(λ µc−β haN)− µ2cd > 0. The characteristic equation (6) at E2 is given by
ζ 4+Aζ 3+Bζ 2+Cζ +D+[−β aNx¯ζ 2+(cβ aNy¯x¯2−β haNx¯−β aNdx¯)ζ
+ cβ aNdy¯x¯2−β hdaNx¯]e−ζτ = 0, (13)
where
A = µ + a+ d+ pz¯+β v¯,
B = aµ + µd+ ad+ pµ z¯+ pdz¯− phz¯+β µ v¯+ aβ v¯+ pβ z¯v¯,
C = adµ + pµhz¯+ phdz¯+ pµdz¯+ aµβ v¯+ phβ z¯v¯+ pµβ z¯v¯,
D = pµhdz¯+ pµhβ z¯v¯− aN pcβ x¯z¯y¯2.
If τ = 0, then the characteristic equation (13) becomes
ζ 4+Eζ 3+Fζ 2+Gζ +H = 0,
where
E = µ + a+ d+ pz¯+β v¯,
F = aµ + µd+ ad+ pµ z¯+ pdz¯− phz¯+β µ v¯+ aβ v¯+ pβ z¯v¯−β aNx¯,
G = adµ + pµhz¯+ phdz¯+ pµdz¯+ aµβ v¯+ phβ z¯v¯+ pµβ z¯v¯−β aNdx¯,
H = pµhdz¯+ pµhβ z¯v¯− aNβ phy¯z¯.
Thus, E > 0, F > 0, G > 0, H > 0 and FG−EH > 0, whenever β N(λ µc−β haN)− µ2cd > 0.
Let τ > 0. Suppose that (13) has pure imaginary roots ζ =ω i. Replacing ζ in (13) by ω i, and separating
the real and imaginary parts, we obtain that
{
ω4− Iω2+ J = Kω2+Lω +M
−Oω3+Nω = Pω2+Qω +R
with
I = aµ + µd+ ad+ pµ z¯+ pdz¯− phz¯+β µ v¯+ aβ v¯+ pβ z¯v¯,
J = pµhdz¯+ pµhβ z¯v¯− aN pcβ x¯z¯y¯2,
K =−β aNx¯cos(ωτ),
L =−cβ aNy¯x¯2 sin(ωτ)+β haNx¯sin(ωτ)+β aNdx¯sin(ωτ),
M =−cβ aNdy¯x¯2 cos(ωτ)+β hdaNx¯cos(ωτ),
N = adµ + pµhz¯+ phdz¯+ pµdz¯+ aµβ v¯+ phβ z¯v¯+ pµβ z¯v¯,
O = µ + a+ d+ pz¯+β v¯,
P = β aNx¯sin(ωτ),
Q =−cβ aNy¯x¯2 cos(ωτ)+β haNx¯cos(ωτ)+β aNdx¯cos(ωτ),
R = cβ aNdy¯x¯2 sin(ωτ)−β hdaNx¯sin(ωτ).
By adding up the squares of both equations, and using the fundamental trigonometric formula, we obtain
that
ω8+ Sω6+Tω4+Uω2+V = 0, (14)
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where
S = O2− 2I,
T = 2J+ I2− 2NO−β 2a2N2x¯2,
U = 2IJ+N2− c2β 2a2N2y¯2x¯4+ 2cβ 2a2N2hy¯x¯3
−β 2a2N2h2x¯2+ 2cβ 2a2N2dy¯x¯3− 2β 2a2N2hdx¯2
−β 2a2N2d2x¯2− 2cβ 2a2N2dy¯x¯3+ 2β 2a2N2hdx¯2,
V = J2+ 2cβ 2a2N2d2hy¯x¯3−β 2h2d2a2N2x¯2.
Equation (14) admits at least two pure imaginary roots. Indeed, let λ = 1, d = 1
10
, β = 1
2
, a = 1
5
, p = 1,
c = 1
10
, h = 1
10
, N = 1500, µ = 1. Then, equation (14) is given by
ω8+
3262009
360000
ω6−
419609
4500000
ω4+
1060237
300000000
ω2+
313
2000000
= 0.
This equation admits four pure imaginary roots; due to length of their writing space, we give here their
approximated values:
0.1550207983i, −0.1550207983i, 3.008467478i and − 3.008467478i.
Therefore, from Rouche´’s theorem, we cannot conclude anything about the stability of E2. Numerically,
however, we can show that the endemic equilibrium E2 is locally asymptotically stable for certain values
of τ . For example, let τ = 10, λ = 1, d = 1
10
, β = 0.00025, p = 0.001, a = 0.2, c = 0.03, N = 1500, and
µ = 3. In this case, it is easy to show analytically that the characteristic equation (13) is given by f (ζ ) = 0
with
f (ζ ) = ζ 4+
1997
600
ζ 3+
121
120
ζ 2+
401
5000
ζ +
1
2000
−
5
8
e−ζτζ 2−
1
16
e−ζτζ .
Thus, f (0)= 1
2000
and the derivative is always positive for τ ≥ 0. Therefore, f (ζ ) does not have nonnegative
real roots. Analogously, we can show numerically that E2 is locally asymptotically stable for some other
positive values of the time delay τ . A general result remains, however, an open question.
3 Optimal control
In this section, we study an optimal control problem associated with the delayed HIV model with CTL
immune response (2).
3.1 The optimization problem
We suggest the following delayed control system with two control variables u1 and u2:

dx(t)
dt
= λ − dx(t)−β (1− u1(t))x(t)v(t),
dy(t)
dt
= β (1− u1(t))x(t − τ)v(t− τ)− ay(t)− py(t)z(t),
dv(t)
dt
= aN(1− u2(t))y(t)− µv(t),
dz(t)
dt
= cx(t)y(t)z(t)− hz(t),
(15)
where the controls belong to the control set U defined by
U =
{
(u1,u2) : ui is measurable, 0≤ ui(t)≤ 1, t ∈ [0, t f ], i = 1,2
}
.
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Here, u1 represents the efficiency of drug therapy in blocking new infections, so that the infection rate in
presence of drug is (1−u1); while u2 stands for the efficiency of drug therapy in inhibiting viral production,
such that the virion production rate under therapy is (1−u2). The optimization problem under consideration
is to maximize the objective functional
J (u1,u2) =
∫ t f
0
{
x(t)+ z(t)−
[
A1
2
u21(t)+
A2
2
u22(t)
]}
dt, (16)
where t f is the time period of treatment and the positive constants A1 and A2 stand for the benefits and costs
of the introduced treatment, subject to the control system (15). The two control functions, u1(·) and u2(·),
are assumed to be bounded and Lebesgue integrable. Summarizing, the optimal control problem under
study consists to find u∗1 and u
∗
2 such that
J(u∗1,u
∗
2) =max{J (u1,u2) : (u1,u2) ∈U}
subject to (15), (3), (4).
(17)
Pontryagin’s minimum principle [8] provides necessary optimality conditions for such optimal control
problem with delays. Roughly speaking, this principle reduces (17) to a problem of maximizing an Hamil-
tonian H pointwisely with respect to u1 and u2. In our case the Hamiltonian is given by
H(x,y,v,z,xτ ,vτ ,u1,u2,ψ1,ψ2,ψ3,ψ4) =
A1
2
u21+
A2
2
u22− x− z+
4
∑
i=0
ψi fi(x,y,v,z,xτ ,vτ ,u1,u2)
with 

f1 = λ − dx−β (1− u1)xv,
f2 = β (1− u1)xτ vτ − ay− pyz,
f3 = aN(1− u2)y− µv,
f4 = cxyz− hz.
By applying Pontryagin’s minimum principle [8], we obtain the following result.
Theorem 5 For any initial conditions (3)–(4), the system (15) has a unique solution. This solution is non-
negative and bounded for all t ≥ 0. In addition, if u∗1 and u
∗
2 are optimal controls and x
∗, y∗, v∗ and z∗
corresponding solutions of the state system (15), then there exists adjoint variables ψ1, ψ2, ψ3 and ψ4
satisfying the adjoint equations


ψ ′1(t) = 1+ψ1(t)
[
d+
(
1− u∗1(t)
)
β v∗(t)
]
−ψ4(t)cy
∗(t)z∗(t)
+χ[0,t f−τ](t)ψ2
(
t + τ
)(
u∗1
(
t + τ
)
− 1
)
β v∗(t),
ψ ′2(t) = ψ2(t)a−ψ3(t)
(
1− u∗2(t)
)
aN−ψ4(t)cx
∗(t)z∗(t)+ψ2(t)pz
∗(t),
ψ ′3(t) = ψ1(t)
[
β (1− u∗1(t))x
∗(t)
]
+ψ3(t)µ + χ[0,t f−τ](t)ψ2(t + τ) [β (u
∗
1(t + τ)− 1)x
∗(t)] ,
ψ ′4(t) = 1+ψ2(t)py
∗(t)+ψ4(t) [h− cx
∗(t)y∗(t)]
with transversality conditions
ψi(t f ) = 0, i = 1, . . . ,4.
Moreover, the optimal controls satisfy
u∗1(t) =min
(
1,max
(
0,
β
A1
[
ψ2(t)v
∗(t − τ)x∗(t − τ)−ψ1(t)v
∗(t)x∗(t)
]))
,
u∗2(t) =min
(
1,max
(
0,
1
A2
ψ3(t)aNy
∗(t)
))
.
(18)
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Proof The proof of positivity and boundedness of solutions is similar to the one of Theorem 1. It is enough
to use the fact that ui(t) ∈U , i = 1,2, which means that ‖ui(t)‖L∞ ≤ 1. For the rest of the proof, we remark
that the adjoint equations and transversality conditions are obtained by using the Pontryagin minimum
principle with delays of [8], from which

ψ ′1(t) =−
∂H
∂x (t)− χ[0,t f−τ](t)
∂H
∂xτ
(t + τ), ψ1(t f ) = 0,
ψ ′2(t) =−
∂H
∂y (t), ψ2(t f ) = 0,
ψ ′3(t) =−
∂H
∂v (t)− χ[0,t f−τ](t)
∂H
∂vτ
(t + τ), ψ3(t f ) = 0,
ψ ′4(t) =−
∂H
∂ z (t), ψ4(t f ) = 0.
From the optimality conditions,
∂H
∂u1
(t) = 0,
∂H
∂u2
(t) = 0,
that is,
A1u1(t)+β ψ1(t)v(t)x(t)−β ψ2(t)v(t − τ)x(t− τ) = 0,
A2u2(t)− aNψ3(t)y(t) = 0.
Taking into account the bounds in U for the two controls, one obtains u∗1 and u
∗
2 in form (18).
3.2 Existence of an optimal control pair
The existence of the optimal control pair can be directly obtained using the results in [7,12]. More precisely,
we have the following theorem.
Theorem 6 There exists an optimal control pair (u∗1,u
∗
2) ∈U solution of (17).
Proof To use the existence result in [7], we first need to check the following properties:
(P1) the set of controls and corresponding state variables is nonempty;
(P2) the control set U is convex and closed;
(P3) the right-hand side of the state system is bounded by a linear function in the state and control variables;
(P4) the integrand of the objective functional is concave on U ;
(P5) there exist constants c1,c2 > 0 and β > 1 such that the integrand
L(x,z,u1,u2) = x+ z−
(
A1
2
u21+
A2
2
u22
)
of the objective functional (16) satisfies
L(x,z,u1,u2)≤ c2− c1(| u1 |
2 + | u2 |
2)
β
2 .
Using the result in [12], we obtain existence of solutions of system (15), which gives condition (P1). The
control set is convex and closed by definition, which gives condition (P2). Since our state system is bilinear
in u1 and u2, the right-hand side of system (15) satisfies condition (P3), using the boundedness of solutions.
Note that the integrand of our objective functional is concave. Also, we have the last needed condition:
L(x,z,u1,u2)≤ c2− c1
(
| u1 |
2 + | u2 |
2
)
,
where c2 depends on the upper bound on x and z, and c1 > 0 since A1 > 0 and A2 > 0. We conclude that
there exists an optimal control pair (u∗1,u
∗
2) ∈U such that
J(u∗1,u
∗
2) = max
(u1,u2)∈U
J (u1,u2)
subject to (15), (3) and (4). The proof is complete.
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3.3 The optimality system
The optimality system consists of the state system coupled with the adjoint equations, the initial conditions,
transversality conditions, and the characterization of optimal controls (18). Precisely, if we substitute the
expressions of u∗1 and u
∗
2 in (15), then we obtain the following optimality system:

dx∗(t)
dt
= λ − dx∗(t)−β (1− u∗1(t))x
∗(t)v∗(t),
dy∗(t)
dt
= β (1− u∗1(t))x
∗(t− τ)v∗(t − τ)− ay∗(t)− py∗(t)z∗(t),
dv∗(t)
dt
= aN(1− u∗2(t))y
∗(t)− µv∗(t),
dz∗(t)
dt
= cx∗(t)y∗(t)z∗(t)− hz∗(t),
dψ1(t)
dt
= 1+ψ1(t)
[
d +
(
1− u∗1(t)
)
β v∗(t)
]
−ψ4(t)cy
∗(t)z∗(t)
+χ[0,t f−τ](t)ψ2
(
t + τ
)(
u∗1
(
t + τ
)
− 1
)
β v∗(t),
dψ2(t)
dt
= ψ2(t)a−ψ3(t)
(
1− u∗2(t)
)
aN−ψ4(t)cx
∗(t)z∗(t)+ψ2(t)pz
∗(t),
dψ3(t)
dt
= ψ1(t)
[
β (1− u∗1(t))x
∗(t)
]
+ψ3(t)µ + χ[0,t f−τ](t)ψ2(t + τ)
[
β (u∗1(t + τ)− 1)x
∗(t)
]
,
dψ4(t)
dt
= 1+ψ2(t)py
∗(t)+ψ4(t)
[
h− cx∗(t)y∗(t)
]
,
u∗1 =min
(
1,max
(
0, β
A1
[
ψ2(t)v
∗
τ x
∗
τ −ψ1(t)v
∗(t)x∗(t)
]))
,
u∗2 =min
(
1,max
(
0, 1
A2
ψ3(t)aNy
∗(t)
))
,
ψi(t f ) = 0, i = 1, . . . ,5.
4 Numerical simulations
In order to solve the optimality system given in Section 3.3, we use a numerical scheme based on forward
and backward finite difference approximations. Precisely, we implemented Algorithm 1.
Remark 1 In our implementation, we choose the initial functions (3), satisfying (4), as x(t)≡ x0, y(t)≡ y0,
v(t)≡ v0, z(t)≡ z0, for all t ∈ [−τ,0] (see Step 1 of Algorithm 1).
In our simulations, the following parameters are used:
λ = 1, d = 0.1, β = 0.00025, p = 0.001, h = 0.2,
a = 0.2, c = 0.03, µ = 3, A1 = 30, A2 = 40, τ = 10.
(19)
Such values respect the HIV parameter ranges given in Table 1. In Figure 1, we use the two following
initial conditions:
x0 = 5, y0 = 1, v0 = 1, z0 = 2 (20)
and
x0 = 45, y0 = 2, v0 = 1, z0 = 4. (21)
Moreover, besides parameters (19), we have chosenN = 750, which means that Nβ λ −dµ =−0.1125< 0.
According to Theorem 2, the disease-free equilibrium E f = (10,0,0,0) is locally asymptotically stable.
The plots of Figure 1 confirm this result of local stability for both initial conditions (20) and (21). In
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Algorithm 1 Numerical algorithm for the optimal control problem (17)
Step 1:
for i =−m, . . . ,0, do:
xi = x0, yi = y0, vi = v0, zi = z0, u
i
1 = 0, u
i
2 = 0
end for;
for i = n, . . . ,n+m, do:
ψ i1 = 0, ψ
i
2 = 0, ψ
i
3 = 0, ψ
i
4 = 0
end for;
Step 2:
for i = 0, . . . , n−1, do:
xi+1 = xi +h[λ −dxi −β(1−u
i
1)xivi],
yi+1 = yi +h[β(1−u
i
1)xi−mvi−m −ayi − pyizi],
vi+1 = vi +h[aN(1−u
i
2)yi −µvi],
zi+1 = zi +h[cxiyizi −hzi],
ψn−i−11 = ψ
n−i
1 −h[1+ψ
n−i
1 (d+(1−u
i
1)βvi+1)−ψ
n−i
4 (cyi+1zi+1)
+ χ[0,t f−τ](tn−i)ψ
n−i+m
2 (u
i+m
1 −1)βvi+1],
ψn−i−12 = ψ
n−i
2 −h[ψ
n−i
2 (a+ pzi+1)−ψ
n−i
2 (aN(1−u
i
2))−ψ
n−i
4 (cxi+1zi+1],
ψn−i−13 = ψ
n−i
3 −h
[
ψn−i1 (1−u
i
1)βxi+1+ψ
n−i
3 µ
+ χ[0,t f−τ](tn−i)ψ
n−i+m
2 (u
i+m
1 −1)xi+1
]
,
ψn−i−14 = ψ
n−i
4 −h[1+ pψ
n−i
2 yi+1+ψ
n−i
4 (h− cxi+1yi+1)],
Ri+11 = (β/A1)(ψ
n−i−1
2 vi−m+1xi−m+1−ψ
n−i−1
1 vi+1xi+1),
Ri+12 = (1/A2)ψ
n−i−1
3 aNyi+1,
ui+11 =min(1,max(R
i+1
1 ,0)),
ui+12 =min(1,max(R
i+1
2 ,0))
end for;
Step 3:
for i = 1, . . . ,n, write:
x∗(ti) = xi, y
∗(ti) = yi, v
∗(ti) = vi, z
∗(ti) = zi, u
∗
1(ti) = u
i
1, u
∗
2(ti) = u
i
2
end for.
Table 1: Parameters, their symbols and meaning, and default values used in HIV literature
Parameters Meaning Value References
λ source rate of CD4+ T cells 1–10 cells µ l−1 days−1 [4]
d decay rate of healthy cells 0.007–0.1 days−1 [4]
β rate at which CD4+ T cells become
infected
0.00025–0.5 µ l virion−1 days−1 [4]
a death rate of infected CD4+ T cells,
not by CTL
0.2–0.3 days−1 [4]
µ clearance rate of virus 2.06–3.81 days−1 [16]
N number of virions produced by in-
fected CD4+ T-cells
6.25–23599.9 virion−1 [3,23]
p clearance rate of infection 1–4.048×10−4 ml virion days−1 [3,14]
c activation rate of CTL cells 0.0051–3.912 days−1 [3]
h death rate of CTL cells 0.004–8.087 days−1 [3]
τ time delay 7–21 days [2,10]
Analysis and optimal control of an intracellular delayed HIV model 13
0 50 100 150 200 2505
10
15
20
25
30
35
40
45
50
Time (days)
U
ni
nf
ec
te
d 
ce
lls
(a) x(t)
0 10 20 30 40 50 600
0.5
1
1.5
2
Time (days)
In
fe
ct
ed
 c
el
ls
(b) y(t)
0 5 10 15 20 25 300
10
20
30
40
50
Time (days)
H
IV
 v
iru
s
(c) v(t)
0 5 10 15 20 25 30 35 400
5
10
15
20
25
Time (days)
CT
Ls
(d) z(t)
Fig. 1: Behavior of infection for N = 750 and parameter values (19). The continuous curves correspond to
initial conditions (20) and dashed curves to initial conditions (21).
Figure 2, we have chosen N = 1500, which means that λ µc−β aNh = 7.50× 10−2 > 0 and Nβ (λ µc−
β haN)− (µ2cd) = 11.245× 10−4 > 0. According to Theorem 4, the endemic equilibrium E2 is locally
stable. Figure 2 confirms this result numerically: we clearly see the convergence to the equilibrium point
E2 = (8.33,0.8,80,8.333). However, it is interesting to point out that, with control, a significant decrease
of the infected cells, free viruses, and CTL cells, is observed (see Figure 2). The uninfected cells get
maximized. It is worth to mention that with control treatment the infection dies very fast and the dynamics
goes toward the disease-free equilibrium. The behavior of the two treatments during time is given in
Figure 3. We can see that the first control makes several switchings from zero to one and vice versa. We
can understand from this that one can manage the first treatment to the patient periodically in full manner.
In this figure, we can also see that the second control is almost equal to one but with sudden decreases, for
some short periods of time, without vanishing.
5 Conclusion
In this work we have studied a delayed HIV viral infection model with CTL immune response. The con-
sidered model includes four differential equations describing the interaction between the uninfected cells,
infected cells, HIV free viruses and CTL immune response. An intracellular time delay and two treatments
are incorporated to the suggested model. First, existence, positivity and boundedness of solutions are es-
tablished. Next, an optimization problem is formulated in order to search the better optimal control pair to
maximize the number of uninfected cells, reduce the infected cells and minimize the viral load. Two control
functions are incorporated in the model, which represent the efficiency of drug treatment in inhibiting viral
production and preventing new infections. The existence of such optimal control pair is established and the
optimality system is given and solved numerically, using a forward and backward difference approximation
scheme. It was shown that the obtained optimal control pair increases considerably the number of CD4+
cells while reducing the number of infected. Moreover, it was also observed that, under optimal control,
the viral load decreases significantly compared with the model without control, which will improve the life
quality of the patient. It remains an open question how to prove stability of the endemic equilibrium E2 of
model (2) for an arbitrary intracellular time delay τ > 0.
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Fig. 2: Behavior of infection during 500 days for N = 1500, parameter values (19), and initial conditions
(20): dotted line without control and without delay (τ = 0); dashed line without control but with delay
τ = 10; continuous line for the delayed problem τ = 10 under optimal control.
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Fig. 3: The two extremal controls u∗1 and u
∗
2 for the delayed optimal control problem (17) with N = 1500,
parameter values (19), and initial conditions (20), obtained using Algorithm 1.
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